OBJECTIVE: To compare the efficiency of contrast-enhanced colour Doppler ultrasound (CECD-US) targeted biopsy versus systematic biopsy (SB) for PCa detection in 1,776 men. METHODS: Retrospective, single-centre, diagnostic accuracy study from 2002 until 2006 in 1,776 male volunteers with a serum total PSA of 1.25 ng/ml or greater. In each patient five CECD-US targeted biopsies were performed in hypervascular areas in the peripheral zone during intravenous injection of a second-generation microbubble US contrast agent. Subsequently, another examiner performed ten SBs. The PCa detection rates for the two techniques were compared. RESULTS: Of 1,776 patients, cancer was detected in 559 patients (31%), including 476 of the 1,776 patients (27%) with CECD-US and 410 (23%) with SB (p < 0.001). The detection rate for CECD-US targeted biopsy cores (10.8% or 961 of 8,880 cores) was significantly better than for SB cores (5.1% or 910 of 17,760 cores, p < 0.001). Among patients with a positive biopsy for PCa, cancer was detected by CECD-US alone in 149 patients (27%) and by SB alone in 83 (15%) (p < 0.001). CONCLUSION: This study represents the largest clinical trial to date, demonstrating a significant benefit of CECD-US targeted biopsy relative to SB.
OBJECTIVE: To compare the efficiency of contrast-enhanced colour Doppler ultrasound (CECD-US) targeted biopsy versus systematic biopsy (SB) for PCa detection in 1,776 men. METHODS: Retrospective, single-centre, diagnostic accuracy study from 2002 until 2006 in 1,776 male volunteers with a serum total PSA of 1.25 ng/ml or greater. In each patient five CECD-US targeted biopsies were performed in hypervascular areas in the peripheral zone during intravenous injection of a second-generation microbubble US contrast agent. Subsequently, another examiner performed ten SBs. The PCa detection rates for the two techniques were compared. RESULTS: Of 1,776 patients, cancer was detected in 559 patients (31%), including 476 of the 1,776 patients (27%) with CECD-US and 410 (23%) with SB (p < 0.001). The detection rate for CECD-US targeted biopsy cores (10.8% or 961 of 8,880 cores) was significantly better than for SB cores (5.1% or 910 of 17,760 cores, p < 0.001). Among patients with a positive biopsy for PCa, cancer was detected by CECD-US alone in 149 patients (27%) and by SB alone in 83 (15%) (p < 0.001). CONCLUSION: This study represents the largest clinical trial to date, demonstrating a significant benefit of CECD-US targeted biopsy relative to SB.
Authors: Margot Wink; Ferdinand Frauscher; David Cosgrove; Jean-Yves Chapelon; Leo Palwein; Michael Mitterberger; Chris Harvey; Olivier Rouvière; Jean de la Rosette; Hessel Wijkstra Journal: Eur Urol Date: 2008-06-20 Impact factor: 20.096
Authors: Richard A Ashley; Brant A Inman; Jonathan C Routh; Lance A Mynderse; Matthew T Gettman; Michael L Blute Journal: Eur Urol Date: 2007-11-05 Impact factor: 20.096
Authors: Michael Mitterberger; Alexandre Pelzer; Daniela Colleselli; Georg Bartsch; Hannes Strasser; Leo Pallwein; Friedrich Aigner; Johann Gradl; Ferdinand Frauscher Journal: Eur J Radiol Date: 2007-09-18 Impact factor: 3.528
Authors: Friedrich Aigner; Leo Pallwein; Michael Mitterberger; Germar M Pinggera; Gregor Mikuz; Wolfgang Horninger; Ferdinand Frauscher Journal: BJU Int Date: 2008-11-18 Impact factor: 5.588
Authors: Robert A Linden; Edouard J Trabulsi; Flemming Forsberg; Paul R Gittens; Leonard G Gomella; Ethan J Halpern Journal: J Urol Date: 2007-10-22 Impact factor: 7.450
Authors: Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto Journal: Curr Opin Urol Date: 2012-07 Impact factor: 2.309